Search Page
Save citations to file
Email citations
Email address has not been verified. Go to
My NCBI account settings
to confirm your email and then refresh this page.
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2025 | 1 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.
Lancet. 2022 Jun 11;399(10342):2200-2211. doi: 10.1016/S0140-6736(22)00688-2.
Lancet. 2022.
PMID: 35691323
Clinical Trial.
Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
Hasskamp J, Meinhardt C, Timmer A.
Hasskamp J, et al.
Cochrane Database Syst Rev. 2025 May 13;5(5):CD007572. doi: 10.1002/14651858.CD007572.pub4.
Cochrane Database Syst Rev. 2025.
PMID: 40357993
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.